PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.Manuel Rodrigues, Sophie Piperno‐Neumann, Zahra Ajgal et al.|Journal of Clinical Oncology|2023Cited by 2
Total tumor volume and growth rate at 3 months on MRI outperform baseline imaging and circulating tumor DNA for predicting survival of patients with metastatic uveal melanoma receiving tebentafuspToulsie Ramtohul, Manuel Alves Rodrígues, Xavier-Louis Jasawant et al.|Diagnostic and Interventional Imaging|2026Cited by 1
MRI-derived tumor burden and growth rate as translational biomarkers: Head-to-head comparison with RECIST and ctDNA in tebentafusp-treated metastatic uveal melanoma.Toulsie Ramtohul, Manuel Rodrigues, Xavier-Louis Jasawant et al.|Journal of Clinical Oncology|2026Cited by 0